Switching from Biosimilar to Biosimilar Adalimumab, Including Multiple Switching, in Crohn’s Disease: A Prospective Study

No data are available regarding the safety and effectiveness of the biosimilar-to-biosimilar switch of adalimumab in any disease, and in particular in Crohn’s disease (CD). The aim of our study was to provide real world data on switching from biosimilar adalimumab to another biosimilar, including mu...

Descripción completa

Detalles Bibliográficos
Autores principales: Ribaldone, Davide Giuseppe, Tribocco, Elisa, Rosso, Chiara, Armandi, Angelo, Vernero, Marta, Bugianesi, Elisabetta, Astegiano, Marco, Saracco, Giorgio Maria, Caviglia, Gian Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8348781/
https://www.ncbi.nlm.nih.gov/pubmed/34362184
http://dx.doi.org/10.3390/jcm10153387

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8348781/
https://www.ncbi.nlm.nih.gov/pubmed/34362184
http://dx.doi.org/10.3390/jcm10153387

Ejemplares similares